openPR Logo
Press release

Dual Antiplatelet Therapy Market 2018: Share, Trends, Analysis, Market Drivers, Growth, Sales, Demand, Research, Opportunities, Future Roadmap, Value Chain, Ecosystem Player Profiles and Strategies, Survey and Industry Forecast to 2028

07-18-2018 03:55 PM CET | Health & Medicine

Press release from: Fact.MR

Fact.MR

Fact.MR

Dual Antiplatelet Therapy Market: Drivers and Restraints

The growing prevalence and recurrence of cardiac diseases is expected to be the major factor driving the growth of the dual antiplatelet therapy market over the forecast period. According to World Health Organization, cardiac disease is the number one cause of death globally. An estimated 17.2 million people die of cardiac diseases, representing 31% of global deaths, annually. Off the 17.2 million people, approximately 7.4 million people died due to coronary heart disease, whereas nearly 6.7 million died due to stroke. Changes in lifestyle and eating habits are attributed to the growing prevalence of cardiac diseases. Research & Development of antiplatelet therapies is another factor contributing to the growth of the global dual antiplatelet therapy market. However, costs associated and lack of awareness about dual antiplatelet therapy market are some of the factors restraining the growth of dual antiplatelet therapy market.

Dual Antiplatelet Therapy Market: Overview

The global market for dual antiplatelet therapy is expected to witness moderate growth over the forecast period. There is a high competition among local and regional players as majority of the antibiotics are introduced in the generic market. Among the two treatment types, the antibiotic treatment segment is expected to lead in the global dual antiplatelet therapy market over the forecast period. Retail pharmacy distribution channel is expected to contribute high share in the global dual antiplatelet therapy market as it is the most accessible channel and majority of the patients are recommended for outpatient treatment.

Dual Antiplatelet Therapy Market: Regional Outlook

Geographically, the global dual antiplatelet therapy market is segmented into viz. North America, Latin America, Europe, Asia Pacific excluding Japan (APEJ), Japan and the Middle East and Africa (MEA). North America is expected to be a dominant market in the global dual antiplatelet therapy market owing to high prevalence of the disease. The dual antiplatelet therapy market in Asia Pacific excluding Japan is expected to grow at a significant CAGR due to increasing prevalence of cardiac diseases. Europe is expected to have the second largest share in the global dual antiplatelet therapy market throughout the forecast period.

To know more about the Dual Antiplatelet Therapy Market Trends, Visit the link – https://www.factmr.com/report/1002/dual-antiplatelet-therapy-market

Dual Antiplatelet Therapy Market: Key Players

The global market for dual antiplatelet therapy is highly fragmented. Examples of some of the key players operating in the global dual antiplatelet therapy market are Bayer AG, Novacap, Shiono Chemical Co., Ltd., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories, Eli Lilly & Co. Ltd. and others.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

The report covers exhaustive analysis on:

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

Regional analysis includes

• North America (U.S., Canada)
• Latin America (Mexico, Brazil)
• Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
• Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
• Asia Pacific Excluding Japan (China, India, Australia & New Zealand)
• Japan
• Middle East and Africa (GCC, S. Africa, Rest Of MEA)

Pre-book this Report- https://www.factmr.com/checkout/1002/S

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dual Antiplatelet Therapy Market 2018: Share, Trends, Analysis, Market Drivers, Growth, Sales, Demand, Research, Opportunities, Future Roadmap, Value Chain, Ecosystem Player Profiles and Strategies, Survey and Industry Forecast to 2028 here

News-ID: 1133672 • Views:

More Releases from Fact.MR

Craft Beer Market is forecasted to reach a value of US$ 174.68 Billion by 2032
04-24-2024 | Food & Beverage
Fact.MR
Craft Beer Market is forecasted to reach a value of US$ 174.68 Billion by 2032
The worldwide craft beer market was expected to be worth $76.3 billion in 2020 and $81.64 billion in 2021. The market will grow at a steady CAGR of 6.9% between 2022 and 2032. By the end of 2032, this market is predicted to have a global valuation of US$174.68 billion. The surge in demand for more beer styles coupled with increase in per capita income among the target customers has triggered
Window Blinds Market Forecasted to Achieve US$ 4.69 Billion by 2034
Window Blinds Market Forecasted to Achieve US$ 4.69 Billion by 2034
The global window blinds market is expected to reach $2.99 billion in 2024, growing at a 5.8% CAGR to $4.69 billion by the end of 2034. Window blinds are adjustable window coverings made of slats or vanes, allowing for versatile control over light and privacy. They come in various materials, including wood, metal, or plastic, and can be easily adjusted to regulate sunlight and maintain privacy. Unlike heavy curtains, blinds are
Vacuum Salt Market is Expected to reach 12,765.2 Million by 2034
04-24-2024 | Food & Beverage
Fact.MR
Vacuum Salt Market is Expected to reach 12,765.2 Million by 2034
The global vacuum salt market is expected to be worth US$ 8,012.3 million in 2024. Projections show a steady expansion with a 4.8% CAGR through 2034. The market is anticipated to be valued at $12,765.2 million by 2034. Growing consumer preference for the ingredient's use in the production of food, as vacuum salt is essential to create a balanced diet, is the factor driving the growth of the global market. The
Hemoglobinopathy Market Forecast Growing at 8.3% CAGR to Reach $1.7 Billion by 2034
04-24-2024 | Health & Medicine
Fact.MR
Hemoglobinopathy Market Forecast Growing at 8.3% CAGR to Reach $1.7 Billion by 2 …
In 2024, the global hemoglobinopathy market (ヘモグロビン症市場) is estimated to be worth US$788.1 million, with a projected compound annual growth rate (CAGR) of 8.3% through 2034. By 2034, the market size is expected to exceed US$1,745.7 million. The rise of genetic testing has led to a significant shift in the hemoglobinopathy market towards personalized medication. Companies are leveraging this trend to develop tailored treatment plans based on each patient's DNA

All 5 Releases


More Releases for Antiplatelet

The Antiplatelet Drugs Market To Thrive Backed By Wearable Technology
Antiplatelet drugs are incorrectly referred to as blood thinners. They do not thin the blood, but interfere with the vital process by which the blood clots. Antiplatelet drugs usually reduce the aggregation of blood cells, reducing potentially harmful clots. Giving antiplatelet drugs to people at high risk of heart disease can help avoid the risk of stroke and heart attack . Get Sample Copy of This Report @
Antiplatelet Drugs Market - Increasing incidence of cardiovascular diseases is e …
The report presents an in-depth assessment of the Antiplatelet Drugs Market including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles, and strategies. The report profiles the key players in the industry, along with a detailed analysis of their individual positions against the global landscape. The study conducts SWOT analysis to evaluate strengths and weaknesses of
Dual Antiplatelet Therapy Market Value Insights, Analysis and Segments 2018 to 2 …
Dual antiplatelet therapy is defined as the use of aspirin and P2Y12 receptor inhibitor to prevent blood clotting, and through a double mechanism, it prevents thrombotic complications. The dual antiplatelet therapy is often prescribed for patients who had a cardiac attack, had coronary artery bypass graft surgery (CABG), or were treated with stents in coronary arteries. Growing prevalence of cardiovascular disease on the coattails of changing lifestyles habits is expected
Dual Antiplatelet Therapy Market: Latest Report with Forecast 2018 to 2028
Platelets are small blood particles that clump together to form clots. Sometimes, these clots may lead to myocardial infarction or a sudden blockage in the coronary artery. Antiplatelets are a class of drugs that inhibit blood clot formation. Many heart attack and stroke patients are treated with two types of antiplatelet drugs to prevent blood clotting. This is known as dual antiplatelet therapy. Dual antiplatelet therapy is a combination therapy
Antiplatelet Drugs Market Registering a Strong Growth by 2025
Antiplatelet drugs are wrongly referred to as the blood thinning drugs. They don’t thin the blood but instead interfere with the important process by which blood clots. Antiplatelet agent normally decrease the clumping of blood cells thereby decreasing the potentially harmful blood clots. People who are at high risk of heart disease when given antiplatelet agents, their risks of strokes and heart attacks can be avoided. Antiplatelet agents are widely used
Antiplatelet Drugs Market Significantly Expand During 2017 - 2025
Antiplatelet drugs are wrongly referred to as the blood thinning drugs. They don’t thin the blood but instead interfere with the important process by which blood clots. Antiplatelet agent normally decrease the clumping of blood cells thereby decreasing the potentially harmful blood clots. People who are at high risk of heart disease when given antiplatelet agents, their risks of strokes and heart attacks can be avoided. Antiplatelet agents are widely used